Background
==========

To determine the therapeutic variability in the treatment of *Candida* colonization or invasive candidiasis (IC) among critically ill patients (pts).

Methods
=======

Prospective observational multicenter study from May 1998--January 1999 in pts staying ≥ 7 days in 73 Spanish intensive care units (ICU). Surveillance cultures were performed weekly from: tracheal aspirates, urine, and gut (oropharynx ± gastric aspirates). The pts were catalogued in two groups: colonized (appearance or persistence of *Candida* in surveillance cultures) and IC (defined as any one or more of the following: candidemia, endophtalmitis, other infections \[OI\]: peritonitis, organ biopsy). Multisite colonization (MC) was defined as ≥ 2 sites positive from surveillance cultures, and persistent MC as positive cultures in ≥ 1 week.

Results
=======

We analyzed 1765 consecutive pts: 961 were considered colonized or infected by *Candida* species, of them, 55 presented candidemia, 35 OI, 7 endophtalmitis, and 864 pts were considered colonized. Were treated with antifungal drugs 48/55 (87.2%), 27/35 (77.1%) and 267/864 (20.9%) of the pts with candidemia, OI and colonized groups, respectively. All pts with endophtalmitis were treated. 57 pts received a second antifungal drug. Fluconazole was the antifungal drugs most used, as the first intention, especially in the colonized groups (86.4%) and less (57.1%) in the endophtalmitis group. The liposomal amphotericin B 18/58 (31.0%) was the most used as the alternative therapeutic. The time of treatment in the ICU was of the 7.7, 10.6, and 5.5.days in the candidemia, OI and endophtalmitis, respectively.

Conclusion
==========

The kind and time of the antifungal treatment was different between the groups analized.
